taurocholic acid has been researched along with Corneal Angiogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, ES; Kim, JY; Kim, MJ; Kim, SY; Tchah, H; Yoon, SY | 1 |
| Kim, JY; Kim, MJ; Moon, BG; Moon, CH; Tchah, H | 1 |
2 other study(ies) available for taurocholic acid and Corneal Angiogenesis
| Article | Year |
|---|---|
Subconjunctival injection of low-molecular-weight heparin-taurocholate 7 inhibits corneal neovascularization.
Topics: Angiogenesis Inhibitors; Animals; Corneal Neovascularization; Disease Models, Animal; Heparin, Low-Molecular-Weight; Injections, Intraocular; Rats; Rats, Sprague-Dawley; Taurocholic Acid; Vascular Endothelial Growth Factor A | 2013 |
Comparison of Topical Low-Molecular-Weight Heparin-Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Bevacizumab; Corneal Neovascularization; Disease Models, Animal; Heparin, Low-Molecular-Weight; Mice; Mice, Inbred BALB C; Ophthalmic Solutions; Taurocholic Acid; Vascular Endothelial Growth Factor A | 2017 |